Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 253 recommendations for 85 medicines and 5 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
6.2. Antibacterials
  1. Amikacin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)
    Second choice
    co-prescribed with cloxacillin Sepsis without septic shock
  2. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
    Indications
    First choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Periapical abscess without sinus Acute otitis media Acute sinusitis co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shock
    Second choice
    Bacterial meningitis
    Other indications
    Infectious cystitis Bacterial infection of unspecified site
  3. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    First choice
    Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Osteomyelitis or osteitis Acute otitis media Other specified prophylactic measures Bacterial infection of joint Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe)
    Other indications
    Bacterial infection of unspecified site
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
    • Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  4. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
    • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritonitis (severe) co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
  5. Azithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    Indications
    First choice
    Chlamydia trachomatis Typhoid fever Yaws Paratyphoid fever Cholera Cholera [children] Trachoma co-prescribed with ceftriaxone Gonococcal infection
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection
  6. Aztreonam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified bacterial diseases
  7. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 20 mg tablet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  8. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
    Indications
    First choice
    Syphilis Congenital syphilis [children]
    Other indications
    Bacterial infection of unspecified site
  9. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
    Indications
    First choice
    Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
  10. Capreomycin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  11. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
    Indications
    First choice
    Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation
    Other indications
    Bacterial infection of unspecified site
  12. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
    Indications
    First choice
    Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
    Other indications
    Surgical site infection
  13. Cefepime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
    Indications
    Other specified bacterial diseases
  14. Cefiderocol General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  15. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
    Indications
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection
  16. Cefotaxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate)
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate) Sepsis without septic shock
    Other indications
    Bacterial infection of unspecified site
  17. Ceftaroline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
    Indications
    Other specified bacterial diseases
  18. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    co-prescribed with vancomycin Endophthalmitis
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic
  19. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  20. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa
  21. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    Indications
    First choice
    Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with vancomycin Endophthalmitis
    Second choice
    Bacterial infection of joint Osteomyelitis or osteitis Infectious gastroenteritis or colitis without specification of infectious agent Sepsis without septic shock Inflammatory and other diseases of prostate (mild to moderate) Acute pyelonephritis (mild to moderate)
    Other indications
    Bacterial infection of unspecified site
  22. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
    Second choice
    Other specified prophylactic measures
  23. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Second choice
    Bacterial meningitis
    Other indications
    Bacterial infection of unspecified site
  24. Ciprofloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Indications
    First choice
    Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Acute pyelonephritis (mild to moderate)
    Second choice
    Cholera Cholera [children] co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate)
    Other indications
    Bacterial infection of unspecified site
  25. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
    • Oral > Solid > dosage form: 500 mg
    Indications
    First choice
    co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)
    Second choice
    Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)
    Other indications
    Helicobacter pylori associated gastric ulcer
  26. Clindamycin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    Indications
    First choice
    co-prescribed with piperacillin + tazobactam Necrotising fasciitis
    Second choice
    Osteomyelitis or osteitis Bacterial infection of joint
    Other indications
    Bacterial infection of unspecified site
  27. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
    Leprosy
  28. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
    Indications
    First choice
    Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis
    Second choice
    co-prescribed with amikacin Sepsis without septic shock
    Other indications
    Bacterial infection of unspecified site
  29. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  30. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  31. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
    Leprosy
  32. Daptomycin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  33. Delafloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
    • Oral > Solid: 450 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  34. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 25 mg
    • Oral > Solid > tablet: 50 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  35. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    • Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dosage form: 100 mg (as hyclate)
    Indications
    First choice
    Chlamydia trachomatis Cholera
    Second choice
    Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Chronic obstructive pulmonary disease with acute exacerbation Cholera [children]
    Other indications
    Bacterial infection of unspecified site
  36. Eravacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg lyophilized powder for injection
    Indications
    Carbapenem resistant Enterobacterales
  37. Erythromycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
    • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
    • Oral > Solid: 250 mg (as stearate or ethylsuccinate)
    Indications
    Second choice
    Therapeutic equivalent to clarithromycin for Acute pharyngitis
    Other indications
    Bacterial infection of unspecified site
  38. Ethambutol General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
    Indications
    Other specified tuberculosis Tuberculosis
  39. Ethambutol + isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  40. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
    Tuberculosis
  41. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
    Tuberculosis
  42. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 125 mg
    • Oral > Solid > tablet: 250 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculous meningitis
  43. Fifth generation cephalosporins General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  44. Flomoxef General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales
  45. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
    Indications
    Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  46. Fourth generation cephalosporins General information
    Section
    Watch group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  47. Gatifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  48. Gentamicin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
    Indications
    First choice
    Neonatal meningitis co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Sepsis without septic shock co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shock
    Second choice
    Other specified prophylactic measures Gonococcal infection
    Other indications
    Bacterial infection of unspecified site
  49. Imipenem + cilastatin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
    Indications
    Second choice
    Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)
    Other indications
    Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis
  50. Imipenem + cilastatin + relebactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
    Indications
    Other specified other antibiotic resistant Enterobacterales Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa
  51. Isoniazid General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 100 mg per mL
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 100 mg; 300 mg
    Indications
    Other specified tuberculosis Tuberculosis
  52. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
    Indications
    Tuberculosis
  53. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 50 mg + 75 mg
    • Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
    Indications
    Tuberculosis
  54. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
    Indications
    Latent tuberculosis
  55. Kanamycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  56. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  57. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  58. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Second choice
    Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  59. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
    Indications
    Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii
  60. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    • Local > Rectal > Suppository: 500 mg; 1 g
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    First choice
    Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with ceftriaxone Necrotising fasciitis co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate)
    Second choice
    co-prescribed with ciprofloxacin Peritonitis (mild-moderate) co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate)
    Other indications
    Bacterial infection of unspecified site
  61. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 100 mg
    • Oral > Solid > tablet: 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis Tuberculosis
  62. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
    First choice
    Infectious cystitis
  63. Ofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  64. Omadacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
    • Oral > Solid: 300 mg
    Indications
    Methicillin resistant Staphylococcus aureus
  65. Oxazolindinones General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  66. P-aminosalicylate sodium General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  67. P-aminosalicylic acid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 4 g granules in sachet
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  68. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
    Indications
    First choice
    Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
    Other indications
    Bacterial infection of unspecified site
  69. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    Peritoneal abscess (severe) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (high-risk) Peritonitis (severe) co-prescribed with clindamycin Necrotising fasciitis
  70. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  71. Polymyxin B (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
    Indications
    Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales
  72. Polymyxins General information
    Section
    Reserve group antibiotics
    • .
    Indications
    Other specified bacterial diseases
  73. Pretomanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  74. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
    First choice
    Congenital syphilis [children]
    Second choice
    Syphilis
  75. Protionamide General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis
  76. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 400 mg; 500 mg
    Indications
    Tuberculosis
  77. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
    Tuberculosis
  78. Rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    • Parenteral > General injections > IV: 600 mg in vial powder for injection
    Indications
    Tuberculosis Other specified tuberculosis
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Leprosy
  79. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 150 mg; 300 mg
    Indications
    Tuberculosis Latent tuberculosis
  80. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
    Second choice
    Gonococcal infection
    Other indications
    Bacterial infection of unspecified site
  81. Streptomycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
    Indications
    Multi-drug resistant Mycobacterium tuberculosis
  82. Sulfamethoxazole + trimethoprim General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    First choice
    Infectious cystitis
    Second choice
    Infectious gastroenteritis or colitis without specification of infectious agent
    Other indications
    Bacterial infection of unspecified site
  83. Tedizolid General information
    Section
    Reserve group antibiotics
    Indications
    Therapeutic equivalent to linezolid for Methicillin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Staphylococcus aureus Therapeutic equivalent to linezolid for Vancomycin resistant Enterococcus
  84. Terizidone General information
    Section
    Antituberculosis medicines
    Indications
    Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis
  85. Tetracycline General information
    Section
    Access group antibiotics
    • Oral > Solid: 250 mg (hydrochloride)
    Indications
    Bacterial infection of unspecified site
  86. Tigecycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    Indications
    Other specified bacterial diseases
  87. Trimethoprim General information
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
    First choice
    Infectious cystitis
  88. Vancomycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    Indications
    First choice
    Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis
    Second choice
    Neutropenia (high-risk) Intestinal infections due to Clostridioides difficile
    Other indications
    Methicillin resistant Staphylococcus aureus